Jyothy Labs Q1 FY27: Growth held up, but crude-linked inflation hit margins

Jyothy Labs reported a steady start to FY27 on the revenue line, but profitability fell sharply as crude-linked raw material and packaging inflation flowed through the P&L. For the quarter ended June 30, 2026 (Q1 FY27), revenue from operations rose to INR 773 crores from INR 751 crores, a 3% year-on-year increase. Operating EBITDA dropped to INR 64.7 crores from INR 124.2 crores, and PAT declined to INR 47.6 crores from INR 96.8 crores.

Management highlighted that the inflation spike was unusual in magnitude and timing. Price increases taken towards the end of March and in April were not sufficient to offset the cost surge, and the company did not benefit from lower-priced older inventory during the quarter. This, combined with intense competitive activity across several SKUs, resulted in a sharp gross margin contraction to 38.5% from 48.0% in the same period last year.

The quarter in numbers

The margin impact was visible across the income statement. Gross margin compressed by 950 basis points year-on-year, which largely explained the EBITDA margin decline to 8.4% from 16.5%. Advertising and promotion spend was moderated to INR 50.6 crores, or 6.5% of revenue, compared with 7.8% a year ago in the investor presentation. Despite lower A&P, profitability could not be protected because the cost inflation was concentrated in the company’s two largest businesses, Fabric Care and Home Care, which management described as heavily linked to crude inputs.

The EBITDA bridge shared in the presentation attributed the decline primarily to gross margin, with a -9.5 percentage point impact, partially offset by lower advertising and sales promotion as a percentage of revenue.

Segment mix: Fabric Care leads, Home Care adjusts post Pril

From Q1 FY27, Jyothy Labs moved to a new segment reporting structure aligned to how management reviews the business under Ind AS 108. The company now reports three segments: Fabric Care, Home Care, and Personal Care. The change matters because it reshapes how investors see the performance drivers and the margin pressure points.

In Q1 FY27, Fabric Care contributed 52% of the business, Home Care 36%, and Personal Care 12%. Fabric Care was the standout, growing 14.1% year-on-year. The segment’s revenue rose to INR 399 crores from INR 349 crores in Q1 FY26. Segment result for Fabric Care was INR 38 crores versus INR 67 crores a year ago, reflecting the cost inflation impact even in the best-performing growth engine.

Home Care was impacted by the Pril exit, which became effective up to May 31, 2026 for sales. Under the new structure, Home Care revenue declined to INR 280 crores from INR 308 crores. The presentation showed Home Care growth of -9.0% when including Pril, and 2.4% when excluding Pril. Management also stated that excluding Pril and Fa, overall revenue growth was 8.1% in value and 5.3% in volume.

Personal Care revenue was flat at INR 94 crores versus INR 94 crores. Management said performance remained subdued due to price increases and transient supply chain disruptions, while also noting emerging inflation in soap noodles from June onwards.

Brand actions and new launches: defend leadership, widen participation

The company’s stated FY27 approach is to defend where it leads and build where it wants to grow. In Fabric Care, it aims to extend post-wash leadership through innovation and use detergents to widen participation across price tiers.

In post-wash, management highlighted sustained digital-first support for Ujala Supreme, distribution ramp-up for Crisp and Shine Intense, and the expansion of Young and Fresh from a strengthened South and West footprint into North markets. In detergents, Ujala Detergent refreshed packaging and improved share in powder and liquid, while Henko continued to play at the premium end supported by sampling to drive liquid trials. The company also reinforced value positioning via promotions and entry packs, including Morelight scaling its liquid at INR 99 for 1 litre and launching a INR 10 pouch.

In Home Care, Exo launched what it described as the category’s first bio-enzymatic dishwash liquid. Management said the product is in early stages, around three to four months post launch, and has delivered reasonably as per expectations, with a more meaningful update expected later in the year. The company also highlighted distribution drives to widen availability across formats.

A second notable launch is Maxo incense sticks. The investor presentation positioned it as a government-approved formula built on Transfluthrin and claimed knockdown in two minutes. Management said the product was launched in July 2026, priced at par with competition, and intended to address consumer concerns around unsafe and unapproved local agarbathies.

In Personal Care, Margo relaunched national communication under a daily skincare theme, with refreshed packs while retaining the core neem-based heritage proposition.

What management is guiding for FY27

Management’s guidance was explicit about near-term pressure and a gradual recovery path. The company expects double-digit revenue growth in FY27 excluding the Pril business. However, EBITDA margins are likely to remain under pressure through the year due to elevated crude-linked input costs, with H2 expected to be substantially better than H1, subject to demand momentum and commodity price stability.

Management also gave a timing marker on cost relief. Even if crude prices remain moderate, raw material and packaging costs are unlikely to correct immediately because higher-cost purchases and contracted inventories will continue to flow through Q2. Any benefit from lower crude-linked inputs is expected to be visible gradually and more meaningfully from October, provided commodity prices remain stable.

On actions, the company highlighted cost optimization, supply chain efficiencies, procurement excellence, value engineering, and selective pricing. Pricing decisions are described as calibrated, taking into account commodity moves, competitive intensity, and consumer demand elasticity.

The call also provided a liquidity datapoint, with the CFO stating net cash balance of about INR 850 crores.

Takeaways

Jyothy Labs entered FY27 with strong momentum in Fabric Care, but Q1 profitability was heavily impacted by an abnormal surge in crude-linked input and packaging costs. Home Care performance is in a transition phase after the Pril exit, with new product scale-up in Exo liquid and format expansion in Maxo positioned as key growth levers.

The core watch item for the next few quarters is the pace of margin recovery. Management expects it to be progressive, with more meaningful cost relief from October if crude-linked inputs remain stable. At the same time, the company plans to sharpen execution in modern trade, e-commerce and quick commerce, and to step up brand investments once the input cost cycle becomes less volatile.

Over the near term, the narrative is clear: growth is being defended through distribution, innovation and channel execution, while profitability is being managed through pricing catch-up and cost actions, with the external crude cycle remaining the swing factor.